In December 2024, the adult sons of Marjorie Tingley received an urgent email from the dementia care unit at Vista Grande Villa, a senior living community in Michigan. The message painted their 85-year-old mother as a serious safety risk. According to behavior logs kept by the facility, Tingley had struck, kicked, or elbowed aides on at least ten days that November, typically when staff tried to change her briefs, dress her, bathe her, or assist her in the bathroom. Vista Grande requested permission to sedate her.
What followed was a bitter, months-long dispute between Tingley's sons and the facility over one of the most divisive issues in long-term care: the use of antipsychotic drugs to calm agitated people living with dementia. These medications carry serious risks. The Food and Drug Administration mandates that pharmaceutical companies warn that such potent drugs raise the likelihood of death in older adults with Alzheimer's disease and related conditions.
The scale of the issue is enormous. More than five million Medicare beneficiaries carry a dementia diagnosis. Despite a 14-year federal campaign aimed at reducing the use of psychotropic medications, roughly one in four Medicare beneficiaries with dementia is potentially inappropriately prescribed antipsychotics and other brain-altering drugs. These medications can trigger delirium, falls, and hospitalizations, according to a study published in JAMA.
For families and guardians, the clash over whether to medicate a loved one is often wrenching and deeply personal. Tingley's sons found themselves caught between two competing fears: the danger their mother might pose to herself and her caregivers, and the danger that sedating drugs might accelerate her decline or even hasten her death. The facility, meanwhile, had its own obligations to protect staff and other residents from injury.
Vista Grande's behavior logs documented repeated incidents of physical aggression. Staff reported being hit, kicked, and elbowed during routine care tasks. Such moments are common in dementia care, where confusion, fear, and an inability to communicate needs can manifest as combativeness. Facilities often turn to antipsychotics when non-drug approaches fail or when staffing shortages make intensive behavioral interventions impractical.
Federal regulators have long urged nursing homes to try alternative strategies first. Since 2012, the Centers for Medicare & Medicaid Services has pushed to reduce antipsychotic prescribing in long-term care, citing the drugs' limited effectiveness for dementia-related agitation and their substantial risks. The effort has produced modest declines in some settings, but the overall rate of prescribing remains stubbornly high.
The JAMA study cited in the source article underscores how widespread the practice remains. Even after years of national attention, a significant share of dementia patients in Medicare continue to receive medications that may do more harm than good. The drugs, known as psychotropics, include antipsychotics, benzodiazepines, and other sedatives. They are sometimes prescribed for legitimate reasons, but often they are used as a chemical restraint—a way to manage behavior without addressing its underlying causes.
For Tingley's family, the dispute with Vista Grande became a case study in those tensions. Her sons wanted to keep her off the medications, fearing the FDA's black-box warning about increased mortality. Vista Grande argued that without sedation, its staff could not safely provide care, and that Tingley herself was at risk of injury during aggressive episodes. The standoff dragged into the new year, leaving the family exhausted and the facility firm in its position.
The emotional toll on families is often overlooked in policy debates. Deciding whether to accept medication for a parent with dementia forces loved ones to weigh immediate safety against long-term well-being, often with incomplete information and under intense time pressure. Guardians may feel they are choosing between two bad outcomes, and the guilt can linger long after the decision is made.
Experts in geriatric care say the problem is not simply one of overprescribing or underprescribing. It is a systemic failure to provide adequate staffing, training, and alternative therapies. Non-drug approaches—such as music therapy, structured routines, and specialized communication techniques—can reduce agitation, but they require time and skilled personnel that many facilities lack. When budgets are tight, medication becomes the cheapest option.
The FDA's warning label on antipsychotics used in elderly dementia patients is explicit: the drugs are not approved for this use, and they increase the risk of death from cardiovascular events, infections, and other causes. Yet off-label prescribing remains common because few other options exist for severe agitation. The result is a nationwide reliance on medications that many clinicians describe as a last resort but that are used far more frequently than that phrase implies.
Tingley's case highlights how difficult it is to change that dynamic. Her sons' resistance to sedation put them at odds with the facility's medical judgment. Vista Grande, for its part, faced its own pressures, including worker safety regulations and the practical realities of caring for residents with advanced dementia. Neither side was acting in bad faith, but the conflict left both feeling unheard.
Advocates for nursing home residents argue that the federal government's voluntary approach has not gone far enough. They call for stricter regulations, better monitoring, and more funding for alternative interventions. Industry groups counter that mandates without resources could leave facilities unable to manage aggressive behaviors, endangering both residents and staff. The debate has grown more urgent as the population ages and dementia diagnoses rise.
For now, families like the Tingley's must navigate these decisions largely on their own. The source article does not say how their dispute was ultimately resolved, but it illuminates the broader dilemma: a care system that too often reaches for a pill when what it needs is more time, more hands, and more humane alternatives. Until those resources materialize, the wrenching choices will continue, one family at a time.
(0)